Literature DB >> 18591383

Toll-like receptors: lessons to learn from normal and malignant human B cells.

David Chiron1, Isabelle Bekeredjian-Ding, Catherine Pellat-Deceunynck, Régis Bataille, Gaëtan Jego.   

Abstract

The humoral immune system senses microbes via recognition of specific microbial molecular motifs by Toll-like receptors (TLRs). These encounters promote plasma cell differentiation and antibody production. Recent studies have demonstrated the importance of the TLR system in enhancing antibody-mediated defense against infections and maintaining memory B cells. These results have led the way to the design of vaccines that target B cells by engaging TLRs. In hematologic malignancies, cells often retain B cell-specific receptors and associated functions. Among these, TLRs are currently exploited to target different subclasses of B-cell leukemia, and TLR agonists are currently being evaluated in clinical trials. However, accumulating evidence suggests that endogenous TLR ligands or chronic infections promote tumor growth, thus providing a need for further investigations to decipher the exact function of TLRs in the B-cell lineage and in neoplastic B cells. The aim of this review is to present and discuss the latest advances with regard to the expression and function of TLRs in both healthy and malignant B cells. Special attention will be focused on the growth-promoting effects of TLR ligands on leukemic B cells and their potential clinical impact.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591383      PMCID: PMC2532798          DOI: 10.1182/blood-2008-02-140673

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

1.  Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

Authors:  Bernd Jahrsdörfer; James E Wooldridge; Sue E Blackwell; Christiana M Taylor; Thomas S Griffith; Brian K Link; George J Weiner
Journal:  J Leukoc Biol       Date:  2004-12-06       Impact factor: 4.962

2.  A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation.

Authors:  Anne Månsson; Mikael Adner; Ulf Höckerfelt; Lars-Olaf Cardell
Journal:  Immunology       Date:  2006-06-16       Impact factor: 7.397

3.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors.

Authors:  G Jego; R Bataille; A Geffroy-Luseau; G Descamps; C Pellat-Deceunynck
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

Review 5.  Toll-like receptors, endogenous ligands, and systemic autoimmune disease.

Authors:  Ian R Rifkin; Elizabeth A Leadbetter; Liliana Busconi; Gregory Viglianti; Ann Marshak-Rothstein
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

6.  Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

Authors:  Isabelle Béatrice Bekeredjian-Ding; Isabelle Béatrice Berkeredjian-Ding; Moritz Wagner; Veit Hornung; Thomas Giese; Max Schnurr; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

Review 7.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

8.  Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response.

Authors:  Marcus Odendahl; Henrik Mei; Bimba F Hoyer; Annett M Jacobi; Arne Hansen; Gwendolin Muehlinghaus; Claudia Berek; Falk Hiepe; Rudi Manz; Andreas Radbruch; Thomas Dörner
Journal:  Blood       Date:  2004-10-26       Impact factor: 22.113

9.  Toll-like receptors mediate proliferation and survival of multiple myeloma cells.

Authors:  J Bohnhorst; T Rasmussen; S H Moen; M Fløttum; L Knudsen; M Børset; T Espevik; A Sundan
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

10.  B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.

Authors:  Bernd Jahrsdorfer; Lars Mühlenhoff; Sue E Blackwell; Moritz Wagner; Hendrik Poeck; Evelyn Hartmann; Ralf Jox; Thomas Giese; Bertold Emmerich; Stefan Endres; George J Weiner; Gunther Hartmann
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

View more
  43 in total

1.  Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma.

Authors:  Basile Siewe; Joey T Pham; Mardge Cohen; Nancy A Hessol; Alexandra Levine; Otoniel Martinez-Maza; Alan Landay
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

2.  The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2011-03-19       Impact factor: 4.132

Review 3.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

4.  Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production.

Authors:  Marcus Dorner; Simone Brandt; Marianne Tinguely; Franziska Zucol; Jean-Pierre Bourquin; Ludwig Zauner; Christoph Berger; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

5.  Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Ariz Akhter; Noraidah Masir; Ghaleb Elyamany; Kean-Chang Phang; Etienne Mahe; Ali Matar Al-Zahrani; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

Review 6.  B-lymphocyte lineage cells and the respiratory system.

Authors:  Atsushi Kato; Kathryn E Hulse; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

7.  Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect.

Authors:  F Eun-Hyung Lee; Jessica L Halliley; Edward E Walsh; Andrew P Moscatiello; Brittany L Kmush; Ann R Falsey; Troy D Randall; Denise A Kaminiski; Richard K Miller; Iñaki Sanz
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

8.  The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.

Authors:  Peter D Crompton; Marko Mircetic; Greta Weiss; Amy Baughman; Chiung-Yu Huang; David J Topham; John J Treanor; Iñaki Sanz; F Eun-Hyung Lee; Anna P Durbin; Kazutoyo Miura; David L Narum; Ruth D Ellis; Elissa Malkin; Gregory E D Mullen; Louis H Miller; Laura B Martin; Susan K Pierce
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Authors:  Céline Berthon; Virginie Driss; Jizhong Liu; Klaudia Kuranda; Xavier Leleu; Nathalie Jouy; Dominique Hetuin; Bruno Quesnel
Journal:  Cancer Immunol Immunother       Date:  2010-09-04       Impact factor: 6.968

10.  B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion.

Authors:  Friederike C Rau; Jacquelyn Dieter; Zhang Luo; Stephen O Priest; Nicole Baumgarth
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.